Long-Term Follow-up of Subjects Who Were Treated With ST-920
Launched by SANGAMO THERAPEUTICS · Sep 1, 2021
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201. All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate. Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects who received ST-920 therapy in a separate parent trial
- • Subjects who have consented to participate in this LTFU study.
- Exclusion Criteria:
- • -This study has no exclusion criteria
About Sangamo Therapeutics
Sangamo Therapeutics is a leading biotechnology company focused on developing transformative genomic therapies for genetic diseases, cancer, and central nervous system disorders. Leveraging its proprietary genome editing technology, including zinc finger protein-based approaches, Sangamo aims to precisely modify genes to address the underlying causes of diseases. With a commitment to innovation and patient-centered solutions, the company engages in extensive clinical trials and collaborations to advance its therapeutic pipeline, striving to bring novel treatments to patients in need and improve health outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Atlanta, Georgia, United States
Cincinnati, Ohio, United States
Irvine, California, United States
Parkville, Victoria, Australia
New York, New York, United States
London, , United Kingdom
Minneapolis, Minnesota, United States
Iowa City, Iowa, United States
Tampa, Florida, United States
Cambridge, , United Kingdom
Würzburg, , Germany
Fairfax, Virginia, United States
Calgary, Alberta, Canada
Patients applied
Trial Officials
Medical Monitor
Study Director
Sangamo Therapeutics, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials